The serum proteomics tracking of hepatocellular carcinoma early recurrence following radical resection
Hongzhi Liu,1,2,* Hui Chen,1,* Xiaomo Wu,3,4 Ying Sun,2 Yingchao Wang,2 Yongyi Zeng,1,2 Geng Chen,2 Xiaolong Liu,2 Xiaohua Xing,2,5 Bixing Zhao,2 Jingfeng Liu1,21Department of Gastrointestinal Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350007, People’s Rep...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-04-01
|
Series: | Cancer Management and Research |
Subjects: | |
Online Access: | https://www.dovepress.com/the-serum-proteomics-tracking-of-hepatocellular-carcinoma-early-recurr-peer-reviewed-article-CMAR |
id |
doaj-6a8004e9b25b4436904c00113d7724ba |
---|---|
record_format |
Article |
spelling |
doaj-6a8004e9b25b4436904c00113d7724ba2020-11-25T00:01:43ZengDove Medical PressCancer Management and Research1179-13222019-04-01Volume 112935294645024The serum proteomics tracking of hepatocellular carcinoma early recurrence following radical resectionLiu HChen HWu XSun YWang YZeng YChen GLiu XXing XZhao BLiu JHongzhi Liu,1,2,* Hui Chen,1,* Xiaomo Wu,3,4 Ying Sun,2 Yingchao Wang,2 Yongyi Zeng,1,2 Geng Chen,2 Xiaolong Liu,2 Xiaohua Xing,2,5 Bixing Zhao,2 Jingfeng Liu1,21Department of Gastrointestinal Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350007, People’s Republic of China; 2The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, People’s Republic of China; 3Department of Biomedicine, University of Basel, Basel 4056, Switzerland; 4Dermatology Institute of Fuzhou, Dermatology Hospital of Fuzhou, Fuzhou 350025, People’s Republic of China; 5The School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350004, People’s Republic of China *These authors contributed equally to this work Purpose: There is still lacking of highly sensitive and specific biomarkers for the prediction of hepatocellular carcinoma (HCC) early recurrence, which has hindered further improvement of the clinical outcomes. We aim to find highly sensitive and specific biomarkers for the prediction of HCC recurrence.Patients and methods: By using isobaric tags for relative and absolute quantitation (iTRAQ)-based multidimensional liquid chromatography-tandem mass spectrometry (2D LC-MS/MS) technique, we have quantitatively investigated and monitored the proteome alterations of a series of serum after radical resection during the follow-up of 4 HCC patients.Results: A total of 27 differentially abundant proteins (DAPs) in serum were identified to be closely associated with the early recurrence of HCC, and these DAPs were particularly concentrated within ERK1/2 and nuclear factor-κ beta signaling pathways, suggesting the dysregulation of these two pathways played an important role in the pathological process of HCC early recurrence. Further investigation of a cohort of patients confirmed that the high serum level of PGK1 was closely associated with HCC early recurrence and poor prognosis. In addition, the serum level of PGK1 could be complementary with AFP to further improve the sensitivity and specificity for predicting the relapse of HCC.Conclusion: PGK1 might be an independent factor for the recurrence of HCC. And the PGK1 could be complementary with AFP to further improve the sensitivity and specificity in prognostic prediction of HCC relapse.Keywords: hepatocellular carcinoma, early recurrence, serum proteomics, iTRAQ, PGK1https://www.dovepress.com/the-serum-proteomics-tracking-of-hepatocellular-carcinoma-early-recurr-peer-reviewed-article-CMARHepatocellular carcinomaearly recurrenceserum proteomicsiTRAQPGK1 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Liu H Chen H Wu X Sun Y Wang Y Zeng Y Chen G Liu X Xing X Zhao B Liu J |
spellingShingle |
Liu H Chen H Wu X Sun Y Wang Y Zeng Y Chen G Liu X Xing X Zhao B Liu J The serum proteomics tracking of hepatocellular carcinoma early recurrence following radical resection Cancer Management and Research Hepatocellular carcinoma early recurrence serum proteomics iTRAQ PGK1 |
author_facet |
Liu H Chen H Wu X Sun Y Wang Y Zeng Y Chen G Liu X Xing X Zhao B Liu J |
author_sort |
Liu H |
title |
The serum proteomics tracking of hepatocellular carcinoma early recurrence following radical resection |
title_short |
The serum proteomics tracking of hepatocellular carcinoma early recurrence following radical resection |
title_full |
The serum proteomics tracking of hepatocellular carcinoma early recurrence following radical resection |
title_fullStr |
The serum proteomics tracking of hepatocellular carcinoma early recurrence following radical resection |
title_full_unstemmed |
The serum proteomics tracking of hepatocellular carcinoma early recurrence following radical resection |
title_sort |
serum proteomics tracking of hepatocellular carcinoma early recurrence following radical resection |
publisher |
Dove Medical Press |
series |
Cancer Management and Research |
issn |
1179-1322 |
publishDate |
2019-04-01 |
description |
Hongzhi Liu,1,2,* Hui Chen,1,* Xiaomo Wu,3,4 Ying Sun,2 Yingchao Wang,2 Yongyi Zeng,1,2 Geng Chen,2 Xiaolong Liu,2 Xiaohua Xing,2,5 Bixing Zhao,2 Jingfeng Liu1,21Department of Gastrointestinal Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350007, People’s Republic of China; 2The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, People’s Republic of China; 3Department of Biomedicine, University of Basel, Basel 4056, Switzerland; 4Dermatology Institute of Fuzhou, Dermatology Hospital of Fuzhou, Fuzhou 350025, People’s Republic of China; 5The School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350004, People’s Republic of China *These authors contributed equally to this work Purpose: There is still lacking of highly sensitive and specific biomarkers for the prediction of hepatocellular carcinoma (HCC) early recurrence, which has hindered further improvement of the clinical outcomes. We aim to find highly sensitive and specific biomarkers for the prediction of HCC recurrence.Patients and methods: By using isobaric tags for relative and absolute quantitation (iTRAQ)-based multidimensional liquid chromatography-tandem mass spectrometry (2D LC-MS/MS) technique, we have quantitatively investigated and monitored the proteome alterations of a series of serum after radical resection during the follow-up of 4 HCC patients.Results: A total of 27 differentially abundant proteins (DAPs) in serum were identified to be closely associated with the early recurrence of HCC, and these DAPs were particularly concentrated within ERK1/2 and nuclear factor-κ beta signaling pathways, suggesting the dysregulation of these two pathways played an important role in the pathological process of HCC early recurrence. Further investigation of a cohort of patients confirmed that the high serum level of PGK1 was closely associated with HCC early recurrence and poor prognosis. In addition, the serum level of PGK1 could be complementary with AFP to further improve the sensitivity and specificity for predicting the relapse of HCC.Conclusion: PGK1 might be an independent factor for the recurrence of HCC. And the PGK1 could be complementary with AFP to further improve the sensitivity and specificity in prognostic prediction of HCC relapse.Keywords: hepatocellular carcinoma, early recurrence, serum proteomics, iTRAQ, PGK1 |
topic |
Hepatocellular carcinoma early recurrence serum proteomics iTRAQ PGK1 |
url |
https://www.dovepress.com/the-serum-proteomics-tracking-of-hepatocellular-carcinoma-early-recurr-peer-reviewed-article-CMAR |
work_keys_str_mv |
AT liuh theserumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection AT chenh theserumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection AT wux theserumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection AT suny theserumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection AT wangy theserumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection AT zengy theserumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection AT cheng theserumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection AT liux theserumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection AT xingx theserumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection AT zhaob theserumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection AT liuj theserumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection AT liuh serumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection AT chenh serumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection AT wux serumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection AT suny serumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection AT wangy serumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection AT zengy serumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection AT cheng serumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection AT liux serumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection AT xingx serumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection AT zhaob serumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection AT liuj serumproteomicstrackingofhepatocellularcarcinomaearlyrecurrencefollowingradicalresection |
_version_ |
1725440803438854144 |